148 related articles for article (PubMed ID: 36536019)
21. Multiparametric MR Index for the Diagnosis of Non-Alcoholic Steatohepatitis in Patients with Non-Alcoholic Fatty Liver Disease.
Kim JW; Lee YS; Park YS; Kim BH; Lee SY; Yeon JE; Lee CH
Sci Rep; 2020 Feb; 10(1):2671. PubMed ID: 32060386
[TBL] [Abstract][Full Text] [Related]
22. MACK-3 (combination of hoMa, Ast and CK18): A promising novel biomarker for fibrotic non-alcoholic steatohepatitis.
Chuah KH; Wan Yusoff WNI; Sthaneshwar P; Nik Mustapha NR; Mahadeva S; Chan WK
Liver Int; 2019 Jul; 39(7):1315-1324. PubMed ID: 30825254
[TBL] [Abstract][Full Text] [Related]
23. The Combination of MR Elastography and Proton Density Fat Fraction Improves Diagnosis of Nonalcoholic Steatohepatitis.
Alsaqal S; Hockings P; Ahlström H; Gummesson A; Hedström A; Hulthe J; Johansson L; Niessen HG; Schoelch C; Schultheis C; Vessby J; Wanders A; Rorsman F; Ebeling Barbier C
J Magn Reson Imaging; 2022 Aug; 56(2):368-379. PubMed ID: 34953171
[TBL] [Abstract][Full Text] [Related]
24. The role of Small Intestinal Bacterial Overgrowth (SIBO) in Non-alcoholic Fatty Liver Disease (NAFLD) patients evaluated using Controlled Attenuation Parameter (CAP) Transient Elastography (TE): a tertiary referral center experience.
Fitriakusumah Y; Lesmana CRA; Bastian WP; Jasirwan COM; Hasan I; Simadibrata M; Kurniawan J; Sulaiman AS; Gani RA
BMC Gastroenterol; 2019 Mar; 19(1):43. PubMed ID: 30894137
[TBL] [Abstract][Full Text] [Related]
25. Controlled attenuation parameter for non-invasive assessment of hepatic steatosis in Chinese patients.
Shen F; Zheng RD; Mi YQ; Wang XY; Pan Q; Chen GY; Cao HX; Chen ML; Xu L; Chen JN; Cao Y; Zhang RN; Xu LM; Fan JG
World J Gastroenterol; 2014 Apr; 20(16):4702-11. PubMed ID: 24782622
[TBL] [Abstract][Full Text] [Related]
26. Utility of transient elastography (fibroscan) and impact of bariatric surgery on nonalcoholic fatty liver disease (NAFLD) in morbidly obese patients.
Garg H; Aggarwal S; Shalimar ; Yadav R; Datta Gupta S; Agarwal L; Agarwal S
Surg Obes Relat Dis; 2018 Jan; 14(1):81-91. PubMed ID: 29126863
[TBL] [Abstract][Full Text] [Related]
27. Comparison of ADAPT, FIB-4 and APRI as non-invasive predictors of liver fibrosis and NASH within the CENTAUR screening population.
Nielsen MJ; Leeming DJ; Goodman Z; Friedman S; Frederiksen P; Rasmussen DGK; Vig P; Seyedkazemi S; Fischer L; Torstenson R; Karsdal MA; Lefebvre E; Sanyal AJ; Ratziu V
J Hepatol; 2021 Dec; 75(6):1292-1300. PubMed ID: 34454994
[TBL] [Abstract][Full Text] [Related]
28. MRI-based (MAST) score accurately identifies patients with NASH and significant fibrosis.
Noureddin M; Truong E; Gornbein JA; Saouaf R; Guindi M; Todo T; Noureddin N; Yang JD; Harrison SA; Alkhouri N
J Hepatol; 2022 Apr; 76(4):781-787. PubMed ID: 34798176
[TBL] [Abstract][Full Text] [Related]
29. Serum levels of soluble dipeptidyl peptidase-4 in type 2 diabetes are associated with severity of liver fibrosis evaluated by transient elastography (FibroScan) and the FAST (FibroScan-AST) score, a novel index of non-alcoholic steatohepatitis with significant fibrosis.
Sagara M; Iijima T; Kase M; Kato K; Sakurai S; Tomaru T; Jojima T; Usui I; Aso Y
J Diabetes Complications; 2021 May; 35(5):107885. PubMed ID: 33602617
[TBL] [Abstract][Full Text] [Related]
30. ADAMTSL2 protein and a soluble biomarker signature identify at-risk non-alcoholic steatohepatitis and fibrosis in adults with NAFLD.
Corey KE; Pitts R; Lai M; Loureiro J; Masia R; Osganian SA; Gustafson JL; Hutter MM; Gee DW; Meireles OR; Witkowski ER; Richards SM; Jacob J; Finkel N; Ngo D; Wang TJ; Gerszten RE; Ukomadu C; Jennings LL
J Hepatol; 2022 Jan; 76(1):25-33. PubMed ID: 34600973
[TBL] [Abstract][Full Text] [Related]
31. Accuracy of Two-Dimensional Shear Wave Elastography and Attenuation Imaging for Evaluation of Patients With Nonalcoholic Steatohepatitis.
Lee DH; Cho EJ; Bae JS; Lee JY; Yu SJ; Kim H; Lee KB; Han JK; Choi BI
Clin Gastroenterol Hepatol; 2021 Apr; 19(4):797-805.e7. PubMed ID: 32450363
[TBL] [Abstract][Full Text] [Related]
32. Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: A systematic review and meta-analysis.
Selvaraj EA; Mózes FE; Jayaswal ANA; Zafarmand MH; Vali Y; Lee JA; Levick CK; Young LAJ; Palaniyappan N; Liu CH; Aithal GP; Romero-Gómez M; Brosnan MJ; Tuthill TA; Anstee QM; Neubauer S; Harrison SA; Bossuyt PM; Pavlides M;
J Hepatol; 2021 Oct; 75(4):770-785. PubMed ID: 33991635
[TBL] [Abstract][Full Text] [Related]
33. Evaluation and comparison of six noninvasive tests for prediction of significant or advanced fibrosis in nonalcoholic fatty liver disease.
Staufer K; Halilbasic E; Spindelboeck W; Eilenberg M; Prager G; Stadlbauer V; Posch A; Munda P; Marculescu R; Obermayer-Pietsch B; Stift J; Lackner C; Trauner M; Stauber RE
United European Gastroenterol J; 2019 Oct; 7(8):1113-1123. PubMed ID: 31662868
[TBL] [Abstract][Full Text] [Related]
34. Accuracy of controlled attenuation parameter for assessing liver steatosis in individuals with morbid obesity before bariatric surgery.
Tavaglione F; De Vincentis A; Bruni V; Gallo IF; Carotti S; Tuccinardi D; Spagnolo G; Ciociola E; Mancina RM; Jamialahmadi O; D'Alessio R; Bottazzi B; Manfrini S; Picardi A; Perrone G; Pozzilli P; Caricato M; Vespasiani-Gentilucci U; Romeo S
Liver Int; 2022 Feb; 42(2):374-383. PubMed ID: 34890093
[TBL] [Abstract][Full Text] [Related]
35. PERFORMACE OF TRIGLYCERIDE-GLUCOSE INDEX ON DIAGNOSIS AND STAGING OF NAFLD IN OBESE PATIENTS.
Smiderle CA; Coral GP; DE Carli LA; Mattos AA; Mattos AZ; Tovo CV
Arq Gastroenterol; 2021; 58(2):139-144. PubMed ID: 34231659
[TBL] [Abstract][Full Text] [Related]
36. Prevalence and risk factors for biopsy-proven non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in a prospective cohort of adult patients with gallstones.
García-Monzón C; Vargas-Castrillón J; Porrero JL; Alonso MT; Bonachía O; Castillo MJ; Marcos A; Quirós E; Ramos B; Sánchez-Cabezudo C; Villar S; Sáez A; Rodríguez de Cía J; del Pozo E; Vega-Piris L; Soto-Fernández S; Lo Iacono O; Miquilena-Colina ME
Liver Int; 2015 Aug; 35(8):1983-91. PubMed ID: 25708133
[TBL] [Abstract][Full Text] [Related]
37. Systematic review with meta-analysis: non-invasive assessment of non-alcoholic fatty liver disease--the role of transient elastography and plasma cytokeratin-18 fragments.
Kwok R; Tse YK; Wong GL; Ha Y; Lee AU; Ngu MC; Chan HL; Wong VW
Aliment Pharmacol Ther; 2014 Feb; 39(3):254-69. PubMed ID: 24308774
[TBL] [Abstract][Full Text] [Related]
38. Clinical validation of the FLIP algorithm and the SAF score in patients with non-alcoholic fatty liver disease.
Nascimbeni F; Bedossa P; Fedchuk L; Pais R; Charlotte F; Lebray P; Poynard T; Ratziu V;
J Hepatol; 2020 May; 72(5):828-838. PubMed ID: 31862486
[TBL] [Abstract][Full Text] [Related]
39. Combination of Aspartate Aminotranferase and Tumor Necrosis Factor-α as Non Invasive Diagnostic Tools for Non Alcoholic Steatohepatitis (NASH).
Purnomo HD; Mundhofir FE; Kasno ; Sudijanto E; Darmono ; Daldiyono ; Djokomoeljanto R; Faradz SM
Acta Med Indones; 2015 Jan; 47(1):16-23. PubMed ID: 25948763
[TBL] [Abstract][Full Text] [Related]
40. Predictive value of ALT levels for non-alcoholic steatohepatitis (NASH) and advanced fibrosis in non-alcoholic fatty liver disease (NAFLD).
Verma S; Jensen D; Hart J; Mohanty SR
Liver Int; 2013 Oct; 33(9):1398-405. PubMed ID: 23763360
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
